SCHEDULE: FMR LLC Reports 4.1% Stake in Vera Therapeutics
Beneficial Ownership Report
FMR LLC and Abigail P. Johnson have disclosed a 4.1% beneficial ownership stake in Vera Therapeutics Inc.'s Class A Common Stock as of December 31, 2025.
Summary
- FMR LLC and Abigail P. Johnson, its Chairman and CEO, beneficially own 2,885,853 shares of Vera Therapeutics Inc. Class A Common Stock.
- This ownership represents 4.1% of the total outstanding Class A Common Stock.
- FMR LLC holds sole voting power over 2,878,610 shares and sole dispositive power over 2,885,853 shares.
- Abigail P. Johnson holds sole dispositive power over 2,885,853 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Vera Therapeutics Inc.
- This filing is an Amendment No. 6 to a previous Schedule 13G statement.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a moderately positive disclosure. The continued presence of a major institutional investor like FMR LLC, even with a stake below 5%, indicates ongoing interest and potential long-term confidence in Vera Therapeutics Inc.
Positives
- A significant institutional investor like FMR LLC holding a stake can signal confidence in Vera Therapeutics Inc.'s long-term prospects.
- The acquisition of shares is stated to be in the ordinary course of business, indicating a standard investment rather than an activist position.
Negatives
- The reported stake of 4.1% is below the 5% threshold, which means FMR LLC is no longer required to file a Schedule 13G unless their ownership increases above 5% again. This could indicate a reduction from a previous higher stake, though the filing itself doesn't specify the prior percentage.
Risks
- No specific risks related to Vera Therapeutics Inc. are detailed in this beneficial ownership disclosure.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding Vera Therapeutics Inc.'s future performance or operations.
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
StockSavvy.ai notes that FMR LLC, a prominent investment management firm, maintaining a significant stake in Vera Therapeutics Inc. suggests continued institutional interest in the biotechnology sector, particularly in companies like Vera Therapeutics that are developing novel therapies. While the stake is below the 5% threshold, the continued disclosure indicates a notable position by a major player in the investment landscape.
Comparison to Industry Standards
- FMR LLC is one of the largest asset managers globally, and its investment in Vera Therapeutics Inc. aligns with typical institutional portfolio diversification strategies within the healthcare and biotechnology sectors.
- Compared to other institutional holdings in similar-sized biotech firms, a 4.1% stake by a firm of FMR LLC's caliber is a substantial, albeit non-controlling, position, often viewed positively by the market as a vote of confidence.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Governance Structure Disclosure (FMR LLC) | Abigail P. Johnson is a Director, Chairman, and CEO of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners of Series B voting common shares of FMR LLC (49% voting power) and have a shareholders' voting agreement, forming a controlling group with respect to FMR LLC. | This details the internal control structure of FMR LLC, the reporting entity, rather than Vera Therapeutics Inc. It clarifies the ultimate control over the investment decisions made by FMR LLC. |
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by FMR LLC may reassure existing shareholders and attract new investors, potentially influencing market perception positively.
- Management: The presence of a large, non-activist institutional investor can provide stability and validation for the company's strategic direction.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC and its subsidiaries. |
| 2023-01-10 | Date of Schedule 13G filing by FMR LLC where Power of Attorney was incorporated by reference (accession number: -23-000003). |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2023-01-31 | Date of Schedule 13G filing by FMR LLC where Abigail P. Johnson's Power of Attorney was incorporated by reference (accession number: -23-000038). |
| 2025-12-31 | Date of event which requires filing of this statement (reporting date for beneficial ownership). |
| 2026-02-04 | Signature date of the Schedule 13G Amendment No. 6. |
Keywords
Vera Therapeutics, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Institutional Investor, Class A Common Stock, SEC Filing, Schedule 13G, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.